KR20110014162A - 항프로게스틴 투여 요법 - Google Patents

항프로게스틴 투여 요법 Download PDF

Info

Publication number
KR20110014162A
KR20110014162A KR20107026587A KR20107026587A KR20110014162A KR 20110014162 A KR20110014162 A KR 20110014162A KR 20107026587 A KR20107026587 A KR 20107026587A KR 20107026587 A KR20107026587 A KR 20107026587A KR 20110014162 A KR20110014162 A KR 20110014162A
Authority
KR
South Korea
Prior art keywords
cdb
administered
compound
progesterone
female
Prior art date
Application number
KR20107026587A
Other languages
English (en)
Korean (ko)
Inventor
조셉 에스. 포돌스키
Original Assignee
레프로스 쎄라피우틱스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레프로스 쎄라피우틱스 아이엔씨. filed Critical 레프로스 쎄라피우틱스 아이엔씨.
Publication of KR20110014162A publication Critical patent/KR20110014162A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
KR20107026587A 2008-04-28 2009-04-27 항프로게스틴 투여 요법 KR20110014162A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4847208P 2008-04-28 2008-04-28
US61/048,472 2008-04-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137009925A Division KR20130059442A (ko) 2008-04-28 2009-04-27 항프로게스틴 투여 요법

Publications (1)

Publication Number Publication Date
KR20110014162A true KR20110014162A (ko) 2011-02-10

Family

ID=40751037

Family Applications (2)

Application Number Title Priority Date Filing Date
KR20107026587A KR20110014162A (ko) 2008-04-28 2009-04-27 항프로게스틴 투여 요법
KR1020137009925A KR20130059442A (ko) 2008-04-28 2009-04-27 항프로게스틴 투여 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137009925A KR20130059442A (ko) 2008-04-28 2009-04-27 항프로게스틴 투여 요법

Country Status (24)

Country Link
US (2) US8426394B2 (de)
EP (1) EP2293797B1 (de)
JP (1) JP5791499B2 (de)
KR (2) KR20110014162A (de)
CN (2) CN102014923A (de)
AR (1) AR071516A1 (de)
AU (1) AU2009241355B2 (de)
BR (1) BRPI0911563A2 (de)
CA (1) CA2722753C (de)
CL (1) CL2009001010A1 (de)
DK (1) DK2293797T3 (de)
EA (3) EA201990835A3 (de)
ES (1) ES2561810T3 (de)
IL (1) IL208844A0 (de)
ME (1) ME01123B (de)
MX (1) MX2010011272A (de)
MY (1) MY161059A (de)
NI (1) NI201000183A (de)
NZ (1) NZ589533A (de)
SG (1) SG10201408483QA (de)
TW (1) TWI477276B (de)
UA (1) UA102849C2 (de)
WO (1) WO2009134718A1 (de)
ZA (1) ZA201007529B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (de) * 2010-12-30 2012-07-04 PregLem S.A. Behandlung von Schmerz in Verbindung mit der Dislokation des basalen Endometriums
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2701400T3 (es) * 2012-05-31 2019-02-22 Repros Therapeutics Inc Formulaciones para la administración vaginal de antiprogestinas
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
JP6343619B2 (ja) * 2012-11-02 2018-06-13 レプロス セラピューティクス インコーポレイティド プロゲステロン依存性病態を処置する方法およびその組成物
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
BR112016029338A2 (pt) 2014-07-29 2017-08-22 Therapeuticsmd Inc creme transdérmico
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
WO1985002092A1 (en) 1983-11-14 1985-05-23 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
HUT74465A (en) * 1993-11-16 1996-12-30 Schering Ag Pharmaceutical composition which useable for treatment of uterine contractility disorders containing a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
JPH10512889A (ja) * 1995-02-02 1998-12-08 シェーリング アクチェンゲゼルシャフト 機能不全性子宮出血を治療する医薬を製造するためのプロゲステロンアンタゴニスト
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
US6861415B2 (en) * 1996-05-01 2005-03-01 The United States Of America As Represented By The Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
AU2805397A (en) 1996-08-30 1998-03-19 Population Council, Center For Biomedical Research, The Vaginal application mifepristone
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
WO2001074840A2 (en) * 2000-03-17 2001-10-11 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregna 21-substituted 19-norpregnadienedione as antiprogestational agents
IN191020B (de) 2000-03-28 2003-09-13 Dabur Res Foundation
WO2001074684A2 (en) 2000-04-03 2001-10-11 Astenjohnson, Inc. Pre-crimped tie components
SI1328276T1 (sl) 2000-10-18 2006-04-30 Schering Ag Uporaba antiprogestinov za profilakso in zdravljenje bolezni, odvisnih od hormonov
DE60228583D1 (de) 2001-07-09 2008-10-09 Repros Therapeutics Inc Verfahren und materialien für die behandlung des testosteron-mangels bei männern
DE602004026173D1 (de) 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
EP1593376A1 (de) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Verbesserte Pullulankapseln
WO2006010097A2 (en) * 2004-07-09 2006-01-26 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
DE102005028970A1 (de) * 2005-06-22 2006-12-28 Siemens Ag Piezoakter mit gesteigertem Hubvermögen
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US8173626B2 (en) 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
SI3263112T1 (sl) * 2006-10-24 2020-10-30 Allergan Pharmaceuticals International Limited Sestavki in metode za zaviranje endometrijskih proliferacij
EP2125858A2 (de) * 2007-01-17 2009-12-02 Repros Therapeutics Inc. Pharmazeutisch akzeptable salze von 11-(4-aminophenyl)-19-norpregna-4,9(10)-dien-3,20-dion-derivaten
US8105625B2 (en) 2007-04-05 2012-01-31 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
WO2008129396A2 (en) 2007-04-20 2008-10-30 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
WO2011039680A1 (en) 2009-09-29 2011-04-07 Koninklijke Philips Electronics N.V. Intrauterine electronic capsule for administering a substance

Also Published As

Publication number Publication date
US8426394B2 (en) 2013-04-23
TWI477276B (zh) 2015-03-21
JP5791499B2 (ja) 2015-10-07
JP2011518845A (ja) 2011-06-30
TW200950786A (en) 2009-12-16
EA201990835A3 (ru) 2019-12-30
CA2722753C (en) 2018-07-03
WO2009134718A1 (en) 2009-11-05
EP2293797A1 (de) 2011-03-16
UA102849C2 (ru) 2013-08-27
CN105616427A (zh) 2016-06-01
EA201401347A1 (ru) 2015-07-30
IL208844A0 (en) 2011-01-31
KR20130059442A (ko) 2013-06-05
ZA201007529B (en) 2011-07-27
ME01123B (me) 2013-03-20
AR071516A1 (es) 2010-06-23
CA2722753A1 (en) 2009-11-05
WO2009134718A8 (en) 2010-09-23
EA201071249A1 (ru) 2011-08-30
US8735381B2 (en) 2014-05-27
CL2009001010A1 (es) 2009-06-19
NI201000183A (es) 2012-06-06
NZ589533A (en) 2012-06-29
SG10201408483QA (en) 2015-02-27
US20110046098A1 (en) 2011-02-24
CN102014923A (zh) 2011-04-13
EP2293797B1 (de) 2015-11-11
MX2010011272A (es) 2010-12-21
MY161059A (en) 2017-04-14
US20130289008A1 (en) 2013-10-31
ES2561810T3 (es) 2016-03-01
EA201990835A2 (ru) 2019-08-30
EA032646B1 (ru) 2019-06-28
BRPI0911563A2 (pt) 2016-07-12
AU2009241355B2 (en) 2013-11-14
AU2009241355A1 (en) 2009-11-05
DK2293797T3 (en) 2016-01-11

Similar Documents

Publication Publication Date Title
JP5791499B2 (ja) 抗プロゲスチンの投薬処方計画
US9616074B2 (en) Compositions and methods for suppressing endometrial proliferation
JP2011518883A (ja) 乳癌を治療するための組成物および方法
US20090118253A1 (en) Compositions and methods for treating dysfunctional uterine bleeding
TW200822931A (en) Compositions and methods for suppressing endometrial proliferation

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
A107 Divisional application of patent
AMND Amendment
E902 Notification of reason for refusal
B601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20130321

Effective date: 20140214